Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan |
| |
| Affiliation: | 1. University of Groningen, University Medical Center Groningen, Department of Epidemiology, P.O. Box 30.001, 9700 RB Groningen, The Netherlands;2. Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA Bilthoven, The Netherlands;3. Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA Bilthoven, The Netherlands;4. Centre for Research Ethics and Bioethics, Uppsala University, PO Box 564, SE-751 22 Uppsala, Sweden;1. Department of Health Outcomes Research and Policy, Auburn University Harrison School of Pharmacy, Auburn, AL;2. Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy, Auburn, AL;3. Auburn University Harrison School of Pharmacy, Auburn, AL;1. Leibniz Institute for Prevention Research and Epidemiology – BIPS, Achterstraße 30, 28359 Bremen, Germany;2. Sanofi Pasteur MSD, Epidemiology Unit, 162, Avenue Jean Jaures, CS50712, 69367 Lyon Cedex 07, France;3. Sanofi Pasteur MSD GmbH, Paul-Ehrlich-Straße 1, 69181 Leimen, Germany;4. Department of Public Health/Health Sciences, University of Bremen, Bremen, Germany;1. Department of Statistics, Sapienza University of Rome, Rome, Italy;2. Center for Information Technology, Bruno Kessler Foundation, Trento, Italy;3. TrentoRise, Trento, Italy;4. Department of Infectious Diseases Epidemiology and Modeling, Norwegian Institute of Public Health, Oslo, Norway;5. Department of Mathematics, University of Rome Tor Vergata, Rome, Italy;6. Department of Economics and Management, University of Pisa, Pisa, Italy |
| |
| Abstract: | BackgroundThe extended use of varicella vaccine in adults aged 50 and older against herpes zoster (HZ) was recently approved in Japan, which has raised the need to evaluate its value for money.MethodsWe conducted a cost-effectiveness analysis with Markov modelling to evaluate the efficiency of varicella vaccine immunisation programme for the elderly in Japan. Four strategies with different ages to receive a shot of vaccine were set, namely: (1) 65–84, (2) 70–84, (3) 75–84 and (4) 80–84 years old (y.o.). Incremental cost-effectiveness ratios (ICERs) compared with no programme from societal perspective were calculated. The health statuses following the target cohort are as follows: without any HZ-related disease, acute HZ followed by recovery, post-herpetic neuralgia (PHN) followed by recovery, post HZ/PHN, and general death. The transition probabilities, utility weights to estimate quality-adjusted life year (QALY) and disease treatment costs were either calculated or cited from literature. Costs of per course of vaccination were assumed at ¥10,000 (US$91). The model with one-year cycle runs until the surviving individual reached 100 y.o.ResultsICERs ranged from ¥2,812,000/US$25,680 to ¥3,644,000/US$33,279 per QALY gained, with 65–84 y.o. strategy having the lowest ICER and 80–84 y.o. strategy the highest. None of the alternatives was strongly dominated by the other, while 80–84 y.o. and 70–84 y.o. strategy were extendedly dominated by 65–84 y.o. strategy. Probabilistic sensitivity analyses showed that the probabilities that ICER is under ¥5,000,000/US$45,662 per QALY gained was at 100% for 65–84 y.o., 70–84 y.o., 75–84 y.o. strategy, respectively, and at 98.4% for 80–84 y.o. strategy.ConclusionWe found that vaccinating individuals aged 65–84, 70–84, 75–84, and 80–84 with varicella vaccine to prevent HZ-associated disease in Japan can be cost-effective from societal perspective, with 65–84 y.o. strategy as the optimal alternative. Results are supported by one-way sensitivity analyses and probabilistic sensitivity analyses. |
| |
| Keywords: | Cost-effectiveness Economic evaluation Herpes zoster Varicella vaccine Vaccination Quality-adjusted life year |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
